Phase 2/3 Study of Monoclonal Antibody Targeting KLRG1 in Inclusion Body Myositis
ICNMD 2026 Presentation

Impact of anti-cytosolic nucleotidase 1A antibody status on disease phenotype and therapeutic response to ulviprubart in inclusion body myositis
EULAR 2026 Presentation

Phase 2/3 study of ulviprubart in inclusion body myositis: Study design, patient characteristics, and topline results
AAN 2026 Presentation

Phase 2/3 study of ulviprubart in inclusion body myositis: Study design, patient characteristics, and topline results
GCOM 2026 Presentation

Patient journey, healthcare resource utilization, and mortality in IBM: A US-based claims analysis
GCOM 2026 Poster

Ulviprubart Pharmacokinetics, Pharmacodynamics, and Safety: Phase 1 Study Results in Patients With Inclusion Body Myositis
WMS 2025 Poster

Ulviprubart Pharmacokinetics, Pharmacodynamics, and Safety: Phase 1 Study Results in Patients With Inclusion Body Myositis
EULAR 2025 Poster

Epidemiology and patient journey in inclusion body myositis: A machine learning methodology applied to claims data in the United States
AAN 2025 Poster

Pharmacokinetics, pharmacodynamics, and safety profile of ulviprubart: Results from a 48-week, open-label, phase 1 study in patients with inclusion body myositis
AAN 2025 Poster

Selective Depletion of KLRG1⁺ T cells in a First-in-Human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM)
GCOM 2022 Poster

Depletion of KLRG1⁺ T cells in a First-in-Human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM)
ACR 2021 Poster

Highly differentiated cytotoxic T cells in inclusion body myositis, Brain, Sept. 2019

Inclusion body myositis: clinical features and pathogenesis, Nat Rev Rheumatol, May, 2019

Association of inclusion body myositis with T cell large granular lymphocytic leukaemia, Brain, May 2016